Montai has dosed the first participants in a Phase 1 trial of MTAI-1025, a novel oral NRF2 agonist for the treatment of ulcerative colitis.

Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic ...

Leading Maternal-Fetal Medicine Experts to Discuss FGR Disease State, the Clinical Rationale for DM199 (Rinvecalinase Alfa) Early Safety and Trial Findings from First Cohort of Phase 2 Early-Onset ...

Evoltix, a power intelligence company built for mission-critical networks, today announced two additions to its Zero-Glitch ...

It sure feels like the Jaguars started some kind of shift against the Patriots. Jaguars wide receiver Brian Thomas Jr. played just 23-of-62 snaps (37%), while the Jaguars had Park ...

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus ...

Fantasy Football is all about the matchups. Even though you drafted your team with certain hopes and intentions, your weekly ...

The second small-business campus at the Trades District, at 676 S. Billingsley Drive in Pangborn Airport Business Park, will ...

EVO301 is a long-acting, native IL-18 binding protein (IL-18BP) fused to a serum albumin binding Fab, designed to neutralize ...

In the last month, Iran-backed Houthi militants in Yemen have joined the Middle East conflict in dramatic fashion – capturing a swathe of the Red Sea coastline, sending ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of ...